Skip to content
ClinCalc Pro
Menu
Human rabies immunoglobulin (HRIG)

Rabies immunoglobulin

Brand names: HyperRAB, Imogam

Rabies immunoglobulin is a preparation of antibodies against rabies virus used as part of post-exposure prophylaxis to provide immediate passive immunity following a high-risk rabies exposure in previously unvaccinated individuals.

Dosing — national schedule

Vaccines and immunoglobulins are given by national schedule or product-specific guidance: see the UK Green Book (UKHSA) and the product's SmPC.

Clinical monograph

How it works

It supplies ready-made neutralising antibodies that bind and inactivate rabies virus at the wound site during the interval before an active immune response to vaccine develops.

Prescribing in practice

  • As much of the dose as possible should be infiltrated into and around the wound, with any remainder given intramuscularly at a site distant from the vaccine to avoid neutralising the vaccine response.
  • It is given together with, but never mixed in the same syringe as, rabies vaccine as part of post-exposure prophylaxis.
  • It is indicated only for unimmunised (or incompletely immunised) people with a significant exposure; those previously fully vaccinated need vaccine boosters rather than immunoglobulin, as advised by specialist services.

Monitoring

Observe for immediate hypersensitivity reactions after administration; no routine laboratory monitoring is required.

Counselling the patient

  • This injection gives immediate protection while the vaccine course builds your own immunity.
  • Thorough wound cleaning and completing the full vaccine schedule are essential.
  • Seek urgent specialist advice without delay after any possible rabies exposure.

Evidence & guidelines

Combined rabies immunoglobulin and vaccine for post-exposure prophylaxis is recommended by WHO and UK Health Security Agency guidance for high-risk exposures.

Reference: UKHSA Green Book Ch.27; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.